Company / R&D per Share
Kymera Therapeutics, Inc. R&D per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.88
FY2025
5-year range
$0.84 / $4.88
FY2021-FY2025
Trend
+12.9%
vs FY2024
Sector context
#35 of 208
Health Care
What the data says
Kymera Therapeutics, Inc.'s r&d per share of $4.88 is higher than 83% of companies in the Health Care sector (FY2025). R&D per Share has increased for 4 consecutive years, from $0.84 in FY2021 to $4.88 in FY2025.
Based on SEC 10-K filings.
4.88 in FY2025 with a 5-year CAGR of -24.0%. Top quartile in the Health Care sector.
Improved from $3.94 to $4.88 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +15.2%
- 5-Year CAGR
- -24.0%
- 10-Year CAGR
- -
Sector benchmark
-60.0% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s r&d per share has grown for 4 consecutive years.
- In FY2025, r&d per share increased 12.9% year-over-year.
- Ranks #35 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.88 | +12.9% |
| FY2024 | $4.32 | +9.7% |
| FY2023 | $3.94 | +23.6% |
| FY2022 | $3.19 | +281.5% |
| FY2021 | $0.84 | -95.7% |
| FY2020 | $19.26 | -12.0% |
| FY2019 | $21.88 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026